Friday, June 14, 2024

TOPICS

Home Tags Rubius Therapeutics

Tag: Rubius Therapeutics

Vacant Rubius property generating interest after 1 year on market

SMITHFIELD – Despite remaining vacant one year after its purchase by Boston-based The Davis Cos., the former Rubius Therapeutics facility in Smithfield has attracted...

Boston firm acquires Rubius Therapeutics facility

SMITHFIELD – Following significant layoffs in the fall, Rubius Therapeutics Inc. has sold its biomanufacturing facility to Boston-based company The Davis Cos. The purchase includes...

PBN’s most-read stories of 2022

From developments with the potential to reshape the landscape of Providence and a steady stream of million-dollar home sales across Rhode Island, to ongoing...

Rubius to lay off about 70 R.I. employees, considering sale of...

SMITHFIELD – Rubius Therapeutics plans to lay off 75% of its workforce, including about 70 of its 101 employees in Rhode Island, and is...

Rubius Therapeutics reports $196.5M loss in 2021

PROVIDENCE – Rubius Therapeutics Inc. on Friday reported a loss of $196.5 million in 2021, or $2.23 per diluted share.  The clinical-stage biopharmaceutical company, which...

Rubius Therapeutics ramps up R&D costs, reports $49M loss in Q3

PROVIDENCE – Rubius Therapeutics Inc. reported a $49 million loss in the third quarter, or 55 cents per diluted share, a decline from a...

Rubius Therapeutics logs $50.2M loss in Q2

CAMBRIDGE, Mass. – The clinical-stage biopharmaceutical company Rubius Therapeutics Inc. reported a loss of $50.2 million in the second quarter, or 56 cents per...

Rubius Therapeutics posts $42.3M loss in Q1

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a $42.3 million loss in the first quarter of 2021, or 51 cents per diluted share, the...
RUBIUS THERAPEUTICS ended 2020 with a loss of $167.7 million.

Rubius Therapeutics reports $167.7M loss in 2020

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported Tuesday a loss of $167.7 million in 2020, or $2.08 per diluted share. The clinical-stage biopharmaceutical company, which...

Rubius Therapeutics reports $40.9M loss in Q3

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a loss of $40.9 million, or 51 cents per diluted share, in the third quarter. The clinical-stage biopharmaceutical...
- Featured Event -

Latest News